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Abstract
Background: We report two novel splice region mutations in OPA1 in two unrelated families presenting with
autosomal-dominant optic atrophy type 1 (ADOA1) (ADOA or Kjer type optic atrophy). Mutations in OPA1 encoding
a mitochondrial inner membrane protein are a major cause of ADOA.
Methods: We analyzed two unrelated families including four affected individuals clinically suspicious of ADOA.
Standard ocular examinations were performed in affected individuals of both families. All coding exons, as well as
exon-intron boundaries of the OPA1 gene were sequenced. In addition, multiplex ligation-dependent probe
amplification (MLPA) was performed to uncover copy number variations in OPA1. mRNA processing was monitored
using RT-PCR and subsequent cDNA analysis.
Results: We report two novel splice region mutations in OPA1 in two unrelated individuals and their affected relatives,
which were previously not described in the literature. In one family the heterozygous insertion and deletion c.[611-37_
611-38insACTGGAGAATGTAAAGGGCTTT;611-6_611-16delCATATTTATCT] was found in all investigated family members
leading to the activation of an intronic cryptic splice site. In the second family sequencing of OPA1 disclosed a de novo
heterozygous deletion c.2012+4_2012+7delAGTA resulting in exon 18 and 19 skipping, which was not detected in
healthy family members.
Conclusion: We identified two novel intronic mutations in OPA1 affecting the correct OPA1 pre-mRNA splicing, which
was confirmed by OPA1 cDNA analysis. This study shows the importance of transcript analysis to determine the
consequences of unclear intronic mutations in OPA1 in proximity to the intron-exon boundaries.
Keywords: OPA1, Splice site mutation, Autosomal dominant optic atrophy, Kjer type optic atrophy, Optic neuropathies
Background
Autosomal dominant optic atrophy type 1 (ADOA1,
MIM#165500), also known as Kjer-type optic atrophy
[1, 2], is the most frequent form of inherited optic neu-
ropathies (ION), with a prevalence ranging from
1:10,000 [3, 4] in Denmark to 1:50,000–30,000 [3–6]
worldwide. ADOA is typically characterized by childhood-
onset insidious moderate to severe progressive bilateral
visual loss, color vision deficits, centrocecal scotoma,
temporal optic nerve pallor and macular ganglion cell loss
[7], which often leads to legal blindness [8–10]. Although
ADOA is genetically heterogeneous [11–13], the vast ma-
jority of ADOA patients (approx. 75%) harbor a mutation
in the OPA1 gene, less frequent mutations in OPA3 and
WFS1 are observed in ADOA patients. OPA1 codes for a
mitochondrial dynamin-like GTPase [14–16], which is an
inner membrane protein targeted to mitochondria by a
highly basic N-terminal import sequence and is anchored
to mitochondrial cristae where it faces the intermembrane
space [17]. OPA1 mRNA is 6492 bp (largest isoform) in
length and has been mapped to chromosome 3q28-q29
[15, 18, 19]. OPA1 consists of 31 exons of which the last
one is non-coding [15, 19]. Through alternative splicing of
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exon 4, 4b and 5b, eight different mRNA isoforms with
different expression patterns in different tissues can be pro-
duced [20]. The OPA1 protein of the main isoform counts
960 amino acids and contains 5 different domains, the N-
terminal hydrophobic mitochondrial targeting domain, a
N-terminal coiled-coil domain, a GTPase domain, a dyna-
min central region and a proposed GTPase effector domain
and the C-terminal coiled-coil domain [14, 21]. OPA1 is
ubiquitously expressed in human tissues with the highest
levels found in retinal ganglion cells and the brain [20, 21].
OPA1 is involved in many different processes. It is the key
player during mitochondrial inner membrane fusion, it
plays a role in mitochondrial DNA, respiratory chain and
membrane potential maintenance, cristae organization by
controlling their shape and structure and it is further
involved in cytochrome c mediated apoptosis [22–25].
More than 340 unique DNA variants have been allocated
to OPA1 (http://mitodyn.org/home.php?select_db=OPA1)
[26]. Half of these mutations result in haploinsufficiency of
OPA1 by premature termination of translation leading to a
truncated protein. Most of these mutations are located in
the GTPase domain, whereas no mutation was found in
the alternatively spliced exons (4, 4b and 5b). The pheno-
typic expression of OPA1 mutations in ADOA shows a
high variability between families as well as members of the
same family [27], often with an incomplete penetrance
ranging from asymptomatic carriers and mild visual impair-
ment to legally blind individuals [28]. ADOA can be classi-
fied either as a non-syndromic or isolated form, presenting
with pure ophthalmologic features or as syndromic form
associated with extra-ocular neurological manifestations,
known as ADOA plus syndrome [5, 29]. Around 20% of
ADOA patients develop additional neuro-muscular fea-
tures, often in the third decade of life, which are sometimes
present at a subclinical level. These include sensorineural
deafness, ataxia, axonal sensory-motor polyneuropathy,
mitochondrial myopathy and external ophthalmoplegia,
whereas in one case parkinsonism and dementia were re-
ported [30]. Many different mutations have been identified
in OPA1 responsible for ADOA, including nonsense muta-
tions, missense mutations, frameshift mutations, in-frame
deletions and splice site or splice region mutations [14, 28,
31]. Since the vast majority of OPA1 mutations are pre-
dicted to result in a premature stop codon, mainly caused
by splice site or splice region, nonsense or frameshift muta-
tions, the generation of a truncated protein leading to hap-
loinsufficiency is proposed to be the major cause for the
pathogenesis of ADOA [28]. The majority of transcripts
containing a premature termination codon (PTC) are
degraded by a mechanism called nonsense-mediated decay
(NMD), which is used to protect the cell from translation
of potentially harmful proteins [32]. In this study we ana-
lyzed all coding exons including the intron-exon boundar-
ies of OPA1 by DNA sequencing of two unrelated families
presenting with clinical features of ADOA. We report two
novel splice region mutations in OPA1, which we character-
ized at RNA level, thereby expanding the mutational
spectrum of OPA1.
Methods
Patients
Family 1
The index patient (III:1, Fig. 1a) was referred to our in-
stitutions at age of 9 years because of reduced vision and
optic disc pallor. The child is the first child of unrelated
parents of Swiss origin. She is normally developed and
besides her vision disorder a healthy child. On the first
examination, best corrected visual acuity (BCVA) for
distance was reduced to 0.3 and 0.5, which dropped to
0.2 and 0.32 at 10 years in the right and left eye, respect-
ively. Temporal optic atrophy was present in both eyes.
The apparently unaffected mother (II:2) showed minor
optic atrophy, which was confirmed by the reduced ret-
inal nerve fiber layer thickness in the papillo-macular
bundle (Fig. 2a). BCVA was normal in the left eye but
reduced to 0.8 in the right eye due to anisometropic am-
blyopia (Fig. 2a). The maternal grandmother (I:2) was
already diagnosed with optic atrophy with mild (age 55:
BCVA 0.7 in both eyes) but progressive vision loss (age
62: BCVA 0.4 and 0.2).
The diagnosis of ADOA was established and molecular
genetic testing performed.
Family 2
The index patient (II:1, Fig. 1b) is the first child of unre-
lated parents of Swiss and Italian origin. The parents (I:1
and I:2) and her younger sister (II:2) did not complain of
any visual dysfunction. There is a possible history of a
mitochondrial disorder with myopathy and ptosis in the
paternal family (paternal grandmother), but no genetic
testing had been performed with regard to this suspicion.
Personal history: The patient was born after an un-
eventful pregnancy and psychomotor development was
normal. At age 14 years she noticed a decrease of visual
acuity at distance. This led to the diagnosis of a myopia
of -1.0 diopters in both eyes and glasses were prescribed.
However, despite best correction, visual acuity remained
at 0.63 in both eyes. Visual field showed few unspecific
defects in the central 30°, mean visual field defect was
1.1 dB and 1.5 dB in the right and the left eye respect-
ively. The patient did not notice difficulties with color
vision and she correctly identified 14 and 13 out of 15
Ishihara color plates with the right eye and the left eye,
respectively. Ophthalmoscopic examination demon-
strated bilateral temporal optic disc pallor (Fig. 2b) and
peripapillary optical coherence tomography showed a
thinning of the retinal nerve fibre layer most pro-
nounced in the papillomacular bundle (Fig. 2b). Visual
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Fig. 1 a and b Pedigrees of the described and analyzed ADOA families. Index patients are indicated with an arrow. Black symbols represent affected
individuals. Symbols containing ‘n.a.’ (not analyzed) indicate individuals with unknown genotype and/or phenotype (not described in this study). c
Sequence analysis of the OPA1 gene at the genomic level. All affected family members of family 1 carrying a heterozygous intronic 22 bp insertion
c.611-37_611-38insACTGGAGAATGTAAAGGGCTTT and a 11 bp deletion c.611-6_611-16delCATATTTATCT (indicated with the arrow). d Sequence
analysis of OPA1 in the index patient of family 2 discloses a heterozygous intronic 4 bp deletion c.2012+4_2012+7AGTA which was absent in healthy
parents and the control
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evoked potentials were not recorded and brain MRI scan
ruled out a compression of the optic nerves. There was
no hearing impairment but diffuse myalgia, which be-
came manifest about the same time as the decrease in
visual acuity. A thorough neurological exam did not
reveal any abnormal findings apart from the visual im-
pairment. Therefore, the tentative diagnosis of ADOA
was made at age 14 years and genetic analysis of the
OPA1 gene was initiated.
Molecular genetic studies
Mutation screening and DNA Sequencing
Genomic DNA (gDNA) was isolated from peripheral
white blood cells of EDTA-stabilized venous blood, using
Prepito DNA Blood600 kit according to the manufac-
turer’s instructions (PerkinElmer, Waltham, MA, USA).
All coding exons (including exon 4b and 5b) of OPA1 as
well as exon-intron boundaries were amplified from
gDNA by PCR (primers and cycling conditions are listed
in Additional file 1: Table S1). All PCR reactions were
performed in a Veriti thermal cycler (Thermo Fisher,
Waltham, MA, USA) and fragments were analyzed using
Qiaxcel DNA High Resolution Cartridge (Qiagen
GmbH, Hilden, Germany). PCR products were ExoSAP
(Thermo Fisher, Waltham, MA, USA) purified and
sequenced using BigDye Terminator chemistry v3.1
(Applied Biosystems, Foster City, CA, USA). Sequen-
cing of both strands was performed on an ABI Prism
3500XL Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA). Sequence data were analyzed with SeqA-
nalysis 6 and SeqScape 3 (Applied Biosystems, Foster City,
CA, USA). MLPA reactions were performed using the
P229 kit from MRC Holland (Amsterdam, Netherlands)
according to the manufacturer’s instructions. Products of
the MLPA reaction were separated on an ABI Prism
3500XL Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA) and were analyzed using GeneMarker
Software v2.6.3. (SoftGenetics, State College, PA, USA)
GenBank transcript NM_130837 was used for variant
numbering using A in ATG as number 1.
OPA1 cDNA analysis
Total RNA was obtained from PAX-blood (family 1, family
2 and a healthy unrelated control subject) using the PAX-
gene Blood RNA kit according to the manufacturer’s
recommendations (PreAnalytiX GmbH, Hombrechtikon,
Switzerland). Random oligohexamer primed RNA (up to
1 μg) was reverse-transcribed using the SuperScript II
First-Strand Synthesis System (Invitrogen, Carlsbad, CA,
USA) in a total volume of 25 μl, according to the manufac-
turer’s protocol. 1 μl of the single-stranded cDNA was used
as template for amplification of fragments extending from
OPA1 exon 4b to 5b (243 bp) and exon 17 to 23 (605 bp),
using the following primer pairs: OPA1-Ex4bF (5’-
CTCAGGTCACAAATTGGTTAGT-3’), OPA1-Ex5bR (5’-
CAACAGAAGCGCAAGGTGTC-3’), and OPA1-Ex17F
A
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Fig. 2 a Color fundus photography depicting optic disc atrophy of the temporal area is more pronounced in the index patient III:1 of family 1
than in her mother II:2. Corresponding retinal nerve fiber layer thickness analysis by optical coherence tomography demonstrating slight (yellow
sectors) to significant reduction (red) in particular within the papillomacular bundle (PMB). b Ophthalmoscopic examination of the index patient
II:1 of family 2 demonstrates bilateral temporal optic disc pallor and peripapillary optical coherence tomography demonstrates a thinning of the
retinal nerve fibre layer most pronounced in the papillomacular bundle
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(5’-TCAAAGCTCCTAAAGACAAGC-3’) and OPA1-
Ex23R (5’-AGCTTGAGGGTTATTCAACA-3’). PCR
conditions using HotStar Taq DNA Polymerase (Qiagen
GmbH, Hilden, Germany) included an initial denatur-
ation step of 15 min at 95 °C, 40 cycles of denaturation
at 94 °C for 30 s, annealing at 55 °C for 30 s,
polymerization at 72 °C for 1 min and a final extension
step at 72 °C for 10 min RT-PCR products were sepa-
rated on a 12% polyacrylamide gel and extracted over-
night in dH2O at 4 °C. Isolated RT-PCR products were
re-amplified using the same cycling conditions and
primers as described above, except of 32 amplification
cycles instead of 40. Re-amplified PCR products were
used for subsequent sequencing as described above.
Results
Mutation analysis in OPA1
All coding exons of OPA1, including exon-intron boundar-
ies, were sequenced and analyzed in two ADOA patients
from two unrelated families (family 1: III:1 and family 2:
II:1) and their family members (Fig. 1a and b). Sequence
analysis of patient 1 (III:1, family 1) revealed a heterozygous
22 bp insertion c.611-37_611-38insACTGGAGAATG
TAAAGGGCTTT proximal of a 11 bp deletion c.611-
6_611-16delCATATTTATCT in intron 5 (Fig. 1c), whereas
the insertion c.611-37_611-38insACTGGAGAATGTAAA
GGGCTTTcould be a potential result of a tandem duplica-
tion (Fig. 4). This sequence alteration is likely to abolish the
3’ acceptor splice site located in intron 5, which was sup-
ported by different in silico prediction tools (Table 1). The
patient’s mother presents with mild visual impairment and
optic atrophy (II:2, family 1) and a grandmother with
reduced vision and optic atrophy (I:2, family 1). Both of
them were found to harbor the same heterozygous c.[611-
37_611-38insACTGGAGAATGTAAAGGGCTTT;611-6_6
11-16delCATATTTATCT] mutation (Fig. 1c).
In index patient 2 (II:1, family 2) we identified a heterozy-
gous 4 bp deletion c.2012 + 4_2012 + 7delAGTA in intron
19 (Fig. 1d), which was reported once in a patient
suspicious for ADOA (http://www.mitodyn.org/vari
ants.php?select_db=OPA1&action=view&view=0000543%2
C0000353%2C0) and classified as variant of unknown clin-
ical significance (VOUS). This mutation was predicted to
abolish the 5’ splice donor site (Table 1). We analyzed fur-
ther both unaffected parents (I:1 and I:2, family 2), who
were negative for the heterozygous c.2012 + 4_2012 +
7delAGTA deletion (Fig. 1d), suggesting the mutation oc-
curred de novo in the index patient. MLPA analysis did not
give any evidence for the presence of the detected intronic
mutations. Furthermore, in both index patients, the three
LHON mutations m.11778G >A, p.(Arg340His) in
MTND4, m.3460G >A, p.(Ala52Thr) in MTND1 and
m.14484 T >C, p.(Met64Val) in MTND6 were not
detected. Also no mutations were found in the nuclear
genes OPA3, TMEM126A and WFS1, thus no other reason
for an opticusatrophy could be identified.
OPA1 cDNA analysis
Both identified deletions have been predicted to alter the
splice sites using different in silico prediction tools
(Table 1). Since OPA1 is expressed in many tissues, in-
cluding the white blood cells [21, 28], we investigate the
impact of the deletions at RNA level using PAX-blood
samples of various family members (family 1 (I:2, II:2
and III:1) and family 2 (I:1, I:2 and II:1)). cDNA analysis
in family 1, showed two transcript species in all investi-
gated and affected family members (family 1: index pa-
tient III.1, mother II:2 and grandmother I:2), including
the wildtype form and an additional larger transcript
(Fig. 3a). Sequence analysis of the transcripts showed
that the c.[611-37_611-38insACTGGAGAATGTAAA
GGGCTTT;611-6_611-16delCATATTTATCT] results in
the activation of a cryptic acceptor splice site, which is
located in the wildtype sequence 166 bp upstream of the
canonical 3’ splice acceptor site. Activation of this cryp-
tic splice site leads to an addition of 177 intronic bases
in the aberrantly spliced mRNA inserting a premature
stop codon in the context of the appropriate reading
frame of this transcript, including the 22 bp insertion
c.611-37_611-38insACTGGAGAATGTAAAGGGCTTT
(Fig. 4), which is also encoded by the gDNA (Fig. 1c).
OPA1 cDNA analysis in family 2 revealed two different
cDNA species, including the wildtype transcript, which
was present in all analyzed individuals including the
control. An additional smaller transcript was reported in
the index patient (Fig. 3b). The unaffected parents, who
do not harbor the deletion showed only the wildtype
form (Fig. 3b). Sequence analysis of the additional
smaller band found in the index patient disclosed a skip-
ping of exons 18 and 19 (Fig. 5). The heterozygous
c.2012 + 4_2012 + 7delAGTA deletion in patient 1 oc-
curred therefore de novo and is likely to be pathogenic,
since it is absent in both healthy parents.
Table 1 In silico prediction of splice score changes of the
natural splice site
Splicing prediction
Prediction Tool Threshold Acceptor Site Donor Site
c.611-16 _611-6del
c.611-37_611-38ins
c.2012 + 4_2012 + 7del
SSF ≥70 87.40⇒— 87.36⇒—
MaxEnt ≥0 7.78⇒— 10.47⇒ 2.39 (-77.2%)
NNSPLICE ≥0.4 0.93⇒— 1.00⇒—
GeneSplicer ≥0 n.a. 2.26⇒—
n.a. not analysed, SSF SpliceSiteFinder-like [39], MaxEnt MaxEntScan [40],
NNSPLICE Splice Site Prediction by Neural Network [41], GeneSplicer [42];
Threshold: minimal value to recognise a putative splice site; - splice
site abolished
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Discussion
OPA1 encodes a protein located in the inner mitochondrial
membrane and is involved in a number of different cellular
processes. It plays a key role during mitochondrial
inner membrane fusion, further it is involved in mito-
chondrial DNA, respiratory chain and membrane
potential maintenance, cristae organization by control-
ling their shape and structure and it has been shown to
play a role in apoptosis [22–25]. Over 300 pathogenic mu-
tations have been reported in OPA1 [33] of which most
mutations lead to the generation of a PTC and result in a
loss of function of one allele (haploinsufficiency), which is
A
B
Fig. 3 Transcript analysis of family 1 (a) and family 2 (b). a All affected relatives of the index patient (III:1) show an additional transcript species
compared to the control. b Index patient (II:1) has an additional transcript compared to the control and the healthy parents
Fig. 4 Sequence analysis of OPA1 transcripts. Sequencing of an additional larger transcript species found in the index patient (III:1) identified an activation
of a cryptic acceptor splice site leading to the retention of intronic sequence containing an insertion of 22 bp c.611-37_611-38ACTGGAGAATGTAAAGG
GCTTT (blue boxes) flanked by intronic sequence (light gray). Red boxes represent the deletion c.611-6_611-16CATATTTATCT. Intronic sequence is written
with small letters and exonic sequence with capital letters. (*) indicates the activation of the cryptic splice site, which is located in the wildtype sequence,
166 bp upstream of the canonical splice site. This transcript species was also identified and sequenced in the affected family members (I:2 and II:2)
(sequence data not shown)
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proposed to be the major mechanism underlying the
pathogenesis of ADOA [20, 28]. The OPA1 protein con-
sists of a hydrophobic transmembrane domain, a GTPase
domain, a middle domain and two C-terminal coiled-coil
domain. Most of the reported mutations are located
within the GTPase domain and the C-terminal coiled-coil
domain (exon 27 and 28) known as mutational hotspots
of OPA1.
Our study indicates that ADOA in two unrelated pa-
tients and their affected family members is caused by
two novel splice region mutations in OPA1. We screened
the entire coding and flanking region of OPA1 in the
two index patients and we identified two novel splice
region mutations. The heterozygous c.[611-37_611-
38insACTGGAGAATGTAAAGGGCTTT;611-6_611-
16delCATATTTATCT] leads to the activation of a cryp-
tic splice site resulting in intron retention and a de novo
heterozygous 4 bp deletion c.2012 + 4_2012 + 7delAGTA
leads to an in-frame exon 18 and 19 skipping. Both het-
erozygous splice region mutations, c.[611-37_611-
38insACTGGAGAATGTAAAGGGCTTT;611-6_611-
16delCATATTTATCT] in intron 5 and c.2012 + 4_2012
+ 7delAGTA in intron 19 of the OPA1 gene, have not
been described before.
The novel splice region mutation c.[611-37_611-38
insACTGGAGAATGTAAAGGGCTTT;611-6_611-16del
CATATTTATCT] identified in family 1 is likely to cause
premature termination of translation of OPA1 by the
formation of a PTC, leading to a truncated protein that
lacks around 80% of the OPA1 protein. Furthermore,
formation of a premature stop codon located within and
not at the end of the transcript, more than 50-55 nucle-
otides upstream of the last exon-exon junction, raises
the possibility that non-sense mediated decay (NMD)
might be involved in degrading aberrant transcripts
[32, 34]. Since we identified a mutant transcript spe-
cies without inhibiting NMD, we conclude that NMD
was not sufficient enough to entirely prevent the ex-
pression of truncated OPA1 and that these small
amounts could interfere with both, the structural as
well as the regulatory function of OPA1 in a negative
way.
The de novo splice region mutation c.2012 + 4_2012 +
7delAGTA found in the affected child of family 2, leads
to an in-frame skipping of exon 18 and 19 which affects
the middle domain of the OPA1 protein. The middle do-
main of dynamins has been shown to be possibly in-
volved in self- and higher-order assembly [35, 36].
Therefore, disruption of the middle domain of OPA1
may result in impaired mitochondrial localization which
further lead to a decreased mitochondrial inner mem-
brane fusion and a subsequent mitochondrial network
fragmentation. Fragmentation of the mitochondrial net-
work triggers decreased energy supply due to the loss of
mitochondrial bioenergetics integrity on one hand and
an increased production of ROS on the other hand. This
leads finally to mitochondrial dysfunction and to cell
death, initiated by the release of cytochrome c from
mitochondria [24].
We suggest that the activation of a cryptic splice site
and the in-frame exon skipping
might affect the OPA1 protein stability. Therefore, we
reason that the mutant OPA1 protein is unstable and
gets rapidly degraded, either through non-sense mediated
decay or another degradation mechanism leading to hap-
loinsufficiency. A further speculative possibility, especially
for the de novo splice region mutation c.2012 + 4_2012 +
7delAGTA, leading to an in-frame exon skipping, could
Fig. 5 Sequence analysis of OPA1 transcripts. Sequencing of the additional smaller transcript species in the index patient (II:1) disclose a skipping
of exon 18 and 19. This transcript species was not found in the healthy parents (sequencing data not shown) and the control
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lead to an altered protein structure and function instead
of resulting in haploinsufficiency, however, this would
need to be elucidated by additional functional studies.
The exact pathomechanism remains unknown and
therefore, further studies, preferably in vivo, would shed
light on the pathogenic mechanisms playing a role dur-
ing development of ADOA caused by OPA1 mutations.
We suggest that in both analyzed families the altered
protein length and structure is likely the mechanism for
ADOA in the affected individuals, therefore, analysis at
the genomic as well as at the RNA level should be per-
formed to investigate OPA1 defects.
Because of the mitochondrial dysfunction and the
resulting impaired energy supply, the optic nerve could be
primarily affected due to its higher sensitivity to energy
deficiency leading to optic atrophy [37] in ADOA. To
understand the pathophysiology of ADOA is important
for the development of novel therapeutic strategies. To
this day, there is no cure for ADOA, but a study per-
formed by Barboni et al. in 2013, showed for the first time
an improved visual function, after application of a syn-
thetic analogue of coenzyme Q10 (Idebenone), an antioxi-
dant used to reduce reactive oxygen species (ROS) levels
in Leber’s hereditary optic neuropathy (LHON) patients,
in ADOA patients with OPA1 mutations [38]. Further,
identification of new mutations and their associated clin-
ical presentation would enable an appropriate genetic
counseling of the patients and their family members. Our
current knowledge about the exact function and the
pathomechanism of OPA1 is far from complete, but iden-
tification of new mutations associated with ADOA and
their functional characterization would give us new in-
sights into the pathogenesis of ADOA.
Conclusion
Many of the reported OPA1 mutations have only been
characterized at the genomic level, only a few splice site or
splice region variants have been investigated at their tran-
script level. In our study, we were able to characterize two
novel splice region mutations at their genomic, as well as
at their RNA level. Our results showed the importance of
cDNA analysis to evaluate the effect of intronic DNA vari-
ants of unknown clinical significance encompassing the
splice regions.
The study further expands the mutational spectrum of
OPA1 in ADOA by the discovery of two novel splice region
mutations and their characterization at the RNA level in
individuals presenting with the clinical picture of an iso-
lated ADOA, since there was no evidence of extra-ocular
features. We could further confirm the variability of intra-
familial phenotypic expression associated with OPA1muta-
tions, which was shown in family 1 with its incomplete
penetrance, ranging from nearly subclinical, mildly affected
individuals to symptomatic family members presenting
with visual impairment and optic atrophy. The clinical
phenotype could be dependent on the quantity of aberrant
OPA1 protein disturbing normal mitochondrial function.
However, the final clinical manifestation is likely to be
influenced by other endogenous and/or environmental
modifying factors.
Additional file
Additional file 1: Additional 5’ M13 Sequence: F: 5’-GTAAAACGA
CGGCCAGT-3’, R: 5’-CAGGAAACAGCTATGAC-3’PCR was performed
according to standard PCR conditions. (DOCX 77 kb)
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